The effectiveness of granulocyte colony-stimulating factor for treatment of non-M3 acute myelogenous leukemia patients.

A clinical trial to compare the effectiveness of the granulocyte colony-stimulating factor with standard treatment in non-M3 acute myelogenous leukemia patients

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20211219053451N1

Enrollment

Registered

2021-12-23

Start date

2022-01-21

Completion date

Unknown

Last updated

2022-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-M3 acute myelogenous leukemia patients. Acute myelomonocytic leukemia

Interventions

Intervention 1: Intervention group: The intervention group will receive 100-200 mg cytarabine for 7 days, 60-90 mg daunorubicin for 3 days and 300 µg granulocyte colony stimulating factor injection on

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Non-M3 acute myelogenous leukemia patients have not received treatment Aged between 18 and 70 years

Exclusion criteria

Exclusion criteria: Secondary acute myeloid leukemia patients Pregnant women with leukemia Patients with other malignancies Having cardiovascular disease Patients with Anaphylactic shock

Design outcomes

Primary

Measure	Time frame
Extinction of disease. Timepoint: 28 days after intervention. Method of measurement: Bone marrow biopsy.;One-year survival of patients. Timepoint: One year after intervention. Method of measurement: Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMostafa Kamandi

Mashhad University of Medical Sciences

kamandim@mums.ac.ir+98 51 3854 3031

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026